鄂尔多斯地区晚期肺腺癌患者一线化疗及TKI治疗的疗效分析  

Comparion of efficacy using chemotherapy or TKI as first-line treatment for advanced lung adenocarcinoma in Erduosi area,China

作　　者：李全福[1] 金高娃[1] 赵镌 胡玉亮[1] 姜彩虹[1] 邓淑琴[1] 

机构地区：[1]鄂尔多斯市中心医院肿瘤科,内蒙古鄂尔多斯017000

出　　处：《现代肿瘤医学》2014年第11期2622-2626,共5页Journal of Modern Oncology

基　　金：内蒙古卫生厅基金资助项目(编号:201303164)

摘　　要：目的:比较鄂尔多斯地区晚期肺腺癌患者一线化疗或TKI疗效。方法:对我院2012年6月至2013年6月收治的Ⅲb-Ⅳ期肺腺癌患者一般情况、基因突变情况、近期疗效、生存情况、毒副反应进行随访分析。结果:晚期肺腺癌EGFR基因送检率44.68%,EGFR基因突变率52.38%。一线联合化疗后接受维持治疗的占69.57%。进展后接受二线治疗的患者比例占90.32%。一线化疗组和一线TKI组的客观有效率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)、中位生存期(MST)、1年生存率分别为39.13%和54.17%、86.96%和83.33%、12.1个月和11.3个月、21.0个月和20.0个月、65.2%和75.0%,两组ORR、DCR、PFS、MST、1年生存率均无显著差异(P>0.05)。化疗组的贫血、骨髓抑制、恶心呕吐、肝功能损害、神经毒性、疲劳乏力、厌食毒副反应高于TKI组,差异有统计学意义(P<0.05);TKI组皮疹和腹泻高于化疗组(P<0.05)。结论:鄂尔多斯地区晚期肺腺癌患者一线化疗和TKI治疗取得了较好的疗效。Objective：To compare efficacy of chemotherapy or TKI as first-line treatment for advanced lung adenocarcinoma in Erduosi area.Methods：To analyze the baseline characteristics,EGFR gene mutation rate,objective response rate,PFS,OS,side-effections of the Ⅲb-Ⅳ stage lung adenocarcinoma.Results：There were 52.38% EGFR gene mutation among 44.68% patients who received EGFR gene testing.There was 69.57% or 90.32% patients who received first-line maintain chemotheraoy or second chemotherapy respectively.The response rate（RR）,disease control rate（DCR）,PFS,median survival time （MST） and 1 year survival rate of first-line chemotherapy regimen and TKI regimen were 39.13% and 54.17%,86.96% and 83.33%,12.1 months and 11.3 months,21.0 months and 20.0 months,65.2% and 75.0% respectively.There was no significant difference in RR,DCR,PFS,MST and 1 year survival rate between two regimens （P 〉 0.05）.Anemia,neutropenia,leukocytopenia,nausea,vomiting,hepatotoxicity,neurotoxic and anorexia of the chemotherapy regimen was significantly higher than that of the TKI regimen （P 〈 0.05）.Wheres rash and diarrhea in the TKI regimen was significantly higher than that of the chemotherapy regimen （P 〈 0.05）.Conclusion：Satisfied efficacy was observed of the Ⅲb-Ⅳ stage lung adenocarcinoma during June 2012 to June 2013 in Erduosi area,china.

关 键 词：化疗 TKI 肺腺癌 鄂尔多斯 

分 类 号：R734.2[医药卫生—肿瘤]